_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
Domestic market and developing countries will need doses of Indian vaccines
The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT
The company has strong product launches both in India and overseas
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Filing for WHO Emergency Use Authorisation this month
This robust growth has come despite the raging pandemic for most part of the quarter
The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Subscribe To Our Newsletter & Stay Updated
